Aldeyra Therapeutics Class Action Lawsuit
Analysis based on 16 articles · First reported Apr 01, 2026 · Last updated Apr 30, 2026
The class action lawsuit against Aldeyra Therapeutics and the negative news regarding its drug candidate, reproxalap, caused a significant drop of approximately 70.7% in Aldeyra Therapeutics' stock price. This event highlights the risks associated with biotechnology companies and their drug development pipelines, potentially leading to increased scrutiny from investors in the sector.
Robbins LLP has filed a class action lawsuit against Aldeyra Therapeutics, alleging that the company misled investors regarding its lead drug candidate, reproxalap. The complaint states that Aldeyra Therapeutics failed to disclose inconsistent results from reproxalap's clinical trials, which rendered any positive findings unreliable. On March 17, 2026, Aldeyra Therapeutics announced receipt of a Complete Response Letter from the United States — United States Securities and Exchange Commission, indicating a lack of substantial evidence for the drug's efficacy in treating dry eye disease. This news led to a significant decline of approximately 70.7% in Aldeyra Therapeutics' stock price.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard